| Literature DB >> 28666950 |
David Yurek1, Ulla Hasselrot2, Ozge Sesenoglu-Laird3, Linas Padegimas4, Mark Cooper3.
Abstract
This study reports proof of concept for administering compacted DNA nanoparticles (DNPs) intracerebrally as a means to protect against neurotoxin-induced neurodegeneration of dopamine (DA) neurons. In this study we used DNPs that encoded for human glial cell line-derived neurotrophic factor (hGDNF); GDNF is a potent neurotrophic factor for DA neurons. Intracerebral injections of DNPs into the striatum and/or substantia nigra were performed 1 week before treatment with a neurotoxin. We observed that the number of surviving DA cells, the density of DA fiber terminals and recovery of motor function were greater in animals injected with GDNF-encoding DNPs than in control animals receiving DNPs encoding for an inert reporter gene. The results of these studies are one of the first to demonstrate that a non-viral, synthetic nanoparticle can be used to deliver therapeutic genes to cells in the brain as a means to protect cells against neurotoxin-induced neurodegeneration.Entities:
Keywords: Gene therapy; Glial cell line-derived neurotrophic factor (GDNF); Lysine polymer; Parkinson's disease; Plasmid DNA
Mesh:
Substances:
Year: 2017 PMID: 28666950 DOI: 10.1016/j.nano.2017.06.010
Source DB: PubMed Journal: Nanomedicine ISSN: 1549-9634 Impact factor: 5.307